1. Controlled and continuous release ocular drug delivery systems: pros and cons;Abdelkader;Curr. Drug Deliv.,2012
2. Abrams, M., Goldberg, D., Luchs, J., Nichols, K., Rauchman, S., Sall, K., et al., 2014. Safety and efficacy of KPI-121 in subjects with inflammatory meibomian gland disease (Maui) [Online]. ClinicalTrials.gov. Kala Pharmaceuticals Inc. Available from: https://clinicaltrials.gov/ct2/show/NCT02218489?term=KPI-121&rank=3 (accessed 07.11.17).
3. Acharya, G., Pflugfelder, S.C., Cintia, P.S., Simpson, J.L., 2012. Therapeutics dispensing device and methods of making same United states patent application.
4. In vitro and ex vivo corneal penetration and absorption models;Agarwal;Drug Deliv. Transl. Res.,2016
5. Modern approaches to the ocular delivery of cyclosporine A;Agarwal;Drug Discov. Today,2016